A Woman’s Struggle with Extreme Pregnancy Sickness
A young woman, Chloe, who faced the possibility of terminating her second pregnancy due to severe sickness, now believes sterilization is her best route, primarily due to the challenges she’s encountered in accessing appropriate treatment.
At just 26, Chloe has experienced hyperemesis gravidarum (HG), a condition marked by relentless nausea and vomiting, often lasting until birth. She expressed that the thought of going through another pregnancy filled her with dread.
Lindsay Whittle, a representative from Plaid Cymru, has been advocating for improved accessibility to Xonvea, a medication specifically designed to address such extreme nausea, which isn’t readily available in Wales.
The Welsh government acknowledges the serious effects that severe pregnancy sickness can bring. They mentioned that healthcare providers have the authority to prescribe a variety of treatments, including Xonvea in select situations.
Chloe, originally from Newport, recalls being hospitalized for dehydration during her first pregnancy, a time when she hadn’t even heard of HG. “I literally spent the entire first trimester in bed, just sucking on ice cubes because I couldn’t keep anything down,” she shared.
During that challenging pregnancy, Chloe sometimes needed assistance with basic self-care, mentioning at times she couldn’t even manage to shower independently. By the time her son was born in 2023, her sickness had finally subsided. Given her turbulent experience with pregnancy, she didn’t plan on having another child but unexpectedly became pregnant again. “When I found out, I turned to my partner and just said, ‘What do we do now?’” she recalls.
As a toddler and baby sleep coach, Chloe faced emotional struggles as well, finding it difficult to maintain her mental health during her pregnancies, particularly due to the constant nausea. At one point, she’d even scheduled an abortion because she felt unable to care for herself and her son—her partner heard her concerns over her safety.
However, an ectopic pregnancy scare led her to a gynecologist who could prescribe Xonvea. The medication is recommended as a primary treatment option by health organizations, although it’s not routinely available in Wales. One pack of 20 tablets costs around £28.50, which is notably higher than other available alternatives.
Recent data indicated that only 223 prescriptions for Xonvea had been issued among Welsh GP practices in October, highlighting the limited access to this treatment.
Chloe mentioned that using Xonvea changed her situation significantly. “It allowed me to resume taking my antidepressants, which helped stabilize my mood. Eventually, I could eat a proper meal,” she stated, adding that she’s now considering a sterilization to avoid the possibility of another pregnancy.
Understanding Hyperemesis Gravidarum
NHS Wales reports that HG affects about one to three in every 100 pregnant women, although many cases remain unreported. Symptoms often include severe nausea, vomiting, weight loss, and dehydration, frequently necessitating hospital treatment.
Dr. Georgina Forbes, a specialist in sexual and reproductive health, underscored the distressing nature of HG and shared her observations of women arriving at abortion clinics because they lacked access to necessary medications. “Women come to me completely at their wits’ end,” she reflects.
Forbes, now chair of the College of Sexual and Reproductive Healthcare’s Wales committee, urged the Welsh government to reassess their stance on Xonvea, arguing the cost of hospitalization far exceeds the price of the medication. Whittle echoed her sentiments, inviting officials to act and calling the issue crucial for many affected families.
In response, the Welsh government reassured that GPs are able to prescribe Xonvea regularly. They rely on guidance from health organizations to advise on medications available on the NHS, emphasizing the necessity for formal recommendations before making drugs routinely accessible.
The All-Wales Medicines Strategy Group stated they are actively discussing options with the medication’s manufacturer, striving to find a resolution for the issue.
